2025 DIA China Annual Meeting
2025 DIA China brings 5000+ life cycle drug development professionals from MNC & Local Pharma Companies, Clinical Study Sites and CROs/CDMOs from 30+ countries and regions. It encourages open collaboration from the entire spectrum of the life science landscape and facilitates discussions across several tracks, such as Regulatory Science, Patient-Centered Clinical Drug Development, AI, Advanced Therapy Medicinal Products (ATMP), Pharmacovigilance and Drug Safety, Drug Development Strategy, Data Science and many more.
Plan to attend our session and stop by our booth #Y01 and talk with our experts to learn how you can benefit from our unparalleled expertise to get results for your trials.
Session information:
Session Title: The importance of cardiovascular safety evaluation in clinical development
Speaker: Vickas Patel, MD, PhD
Roundtable Discussion: How to effectively address important safety issues in clinical development
Speakers: Vickas Patel, MD, PhD, Onglee Weng, Prof. Haiyan Li
Abstract:
The 2025 DIA Annual Meeting’s special session on drug safety and pharmacovigilance was co-chaired by Liang Bing, Head of Drug Safety in the Asia-Pacific Region of Pfizer (China) Research and Development Co., Ltd., and Shuguang Ren, Head of Advanced Benefit Risk Assessment and Senior Director of Bayer (China).
Clario experts will discuss with you an in-depth look at the critical assessment of cardiovascular safety issues in clinical development – how to identify and manage the potential cardiac risks associated with new treatment options. We’ll share cutting-edge insights on common safety issues in clinical development and take you through the latest approaches to cardiac safety assessment, including current and future advanced technologies and innovative practices.
Dr. Patel will present a keynote speech on “The Importance of Cardiovascular Safety Evaluation in Clinical Development”, providing an in-depth understanding of the critical role of cardiovascular safety evaluation in clinical development.
Special Guests: Onglee Weng and Prof. Haiyan Li will join Dr. Patel in a roundtable discussion to share how to effectively address important safety issues in clinical development, discuss the latest regulatory guidelines, best practices, and emerging trends, and cover challenges and solutions to cardiac safety and other clinical safety issues.
Speakers
Vickas Patel, M.D., Ph.D.
Vice President and Chief Medical Officer, Cardiology at Clario
Vic Patel, MD, PhD, is board certified in cardiology with a PhD in Biophysics and has done extensive research on mechanisms of cardiac arrhythmias. He was on faculty at U. Penn. School Medicine for 11 years where he directed Molecular Arrhythmia Research and practiced clinical electrophysiology. Dr. Patel then moved into drug development and cardiac safety as a clinical development leader and therapy area head across all phases. At Clario, Dr. Patel oversees cardiology science and research, the consulting and ECG/Holter core lab services and he also leads the biostatistics and medical writing groups. He works with our global customers to ensure their needs are met with robust, cost-effective solutions.
Onglee Weng, M.D.
Vice President, General Manager, Clario-Shanghai and Cardiology at Clario-Shanghai
Onglee Weng is the Vice President, General Manager, Clario-Shanghai. She has 20+ years of work experience in the drug R&D industry with 10+ years of overseas work experience. She was a licensed physician in Shanghai China before joining Clario (and its former companies) over 18 years ago. Dr. Weng led her team to successfully complete the first TQT trials in China and Japan. She also directed her team in completing ICH E14 and site trainings for several national leading phase I clinical centers in China, and jointly completed several research papers that have been published in international journals. Dr. Wend has participated in the formulation of ICH E14 & S7B Chinese translation and technical guidelines invited by China CDE. In her current role, she is responsible for managing both Clario’s medical imaging business and cardiovascular safety business in the Chinese market.
Meet with us at 2025 DIA China Annual Meeting.
Complete this form and we will reach out soon to schedule a time to connect at the event.
If you are a company wishing to collaborate with us, please stop by our booth during the conference to talk with our team.